If blarcamesine is the disease modifying drug we believe it to be, the market will enlarge as the number of AD survivors grow. So that 4M estimate would move upwards, depending on just how effective the drug may be in extending the time of early AD. (Not to mention off-label possibilities, such as MCI [a very large population], PD and other neuro diseases.)
Market Data 
Markets 
AI
